Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Improvement in Hepatitis “C” viral infection with advanced antiviral therapy,treatment – a meta-analysis
Södertörn University, School of Natural Sciences, Technology and Environmental Studies.
2015 (English)Independent thesis Advanced level (degree of Master (One Year)), 10 credits / 15 HE creditsStudent thesis
Abstract [en]

Background: Hepatitis is the inflammation of liver and there are many reasons of hepatitis. Among these reasons the viral hepatitis due to hepatitis B virus (HBV) and hepatitis C Virus (HCV) are the common hepatic infections and the major causes of liver cancer and liver cirrhosis in the world especially in Asia and Medal east. HBV and HCV infections are having very high mortality ratio in Europe and every year millions of people become infected and die due to HBV or HCV in Europe and Worldwide. That’s why viral hepatitis needs a serious consideration and perfect treatment.

Objective: Objective of the study was to analyze the role of ribavirin in HCV treatment and to observe the virological response and relapse against it by using statistical meta-analytical techniques.

Selection criteria and data collection: For this meta-analysis I used the publication databases PubMed, ScienceDirect and Google Scholar to collect all research articles describing treatment and response of HCV and using the antiviral drugs Ledipasvir and Sofosbuvir (control group) in combination with the active agent Ribavirin.

Method and Methodology: Meta-analysis was performed using the statistical package R and the package metafore.

Result and conclusion: The result shows that the use of ribavirin with control group (ledipasvir and sofosbuvir) did not show a significant impact on the sustained virological response (SVR) during and after treatment. But addition of ribavirin in control group effectively reduced the rate of relapse after treatment.

Place, publisher, year, edition, pages
2015. , 23 p.
National Category
Infectious Medicine
Identifiers
URN: urn:nbn:se:sh:diva-27817OAI: oai:DiVA.org:sh-27817DiVA: diva2:824066
Subject / course
Molecular Biology
Presentation
2015-06-05, Södertörns högskola, Stockholm, 09:02 (English)
Uppsok
Life Earth Science
Supervisors
Examiners
Available from: 2015-06-22 Created: 2015-06-20 Last updated: 2015-06-22Bibliographically approved

Open Access in DiVA

fulltext(502 kB)307 downloads
File information
File name FULLTEXT01.pdfFile size 502 kBChecksum SHA-512
3cf46bf260ebe837ac5fb0b16d896e4ffe6edbc02426b96776c24fdc79ec5158c3c0ab382e3354a3dbc2930ce87d4cc0907b5dcb2dce7184ee7601fa727b0aa4
Type fulltextMimetype application/pdf

By organisation
School of Natural Sciences, Technology and Environmental Studies
Infectious Medicine

Search outside of DiVA

GoogleGoogle Scholar
Total: 307 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

urn-nbn

Altmetric score

urn-nbn
Total: 287 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf